Angiotensin II in General Anesthesia

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs). Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborator: La Jolla Pharmaceutical Company
• Treatments: Anesthetics; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Antihypertensive Agents; Enzyme Inhibitors; Giapreza

Criteria

Inclusion Criteria:

• Diagnosis of hypertension and treatment with at least one medication including an ACE inhibitor, ARB, and other agents for greater than 2 months

• Patients undergoing general anesthesia

Exclusion Criteria:

• BMI > 40

• History of deep venous thrombosis / thromboembolic disease

• History of stroke,

• Baseline SBP of ≥ 160 mmHg,

• History of myocardial infarction or cardiac stents

• Difficult airway

• Asthma

• Congestive heart failure

• Chronic obstructive pulmonary disease

• Pregnant patients